Efficacy and safety/tolerability of Grass MATA MPL a randomized, placebo-controlled, double-blind study.

Trial Profile

Efficacy and safety/tolerability of Grass MATA MPL a randomized, placebo-controlled, double-blind study.

Completed
Phase of Trial: Phase III

Latest Information Update: 02 Jun 2011

At a glance

  • Drugs Grass pollen allergy immunotherapy (Primary)
  • Indications Grass pollen hypersensitivity; Rhinoconjunctivitis; Seasonal allergic rhinitis
  • Focus Registrational; Therapeutic Use
  • Sponsors Allergy Therapeutics
  • Most Recent Events

    • 29 Apr 2011 Results published in Allergy and Asthma Proceedings.
    • 22 Mar 2011 Subgroup analysis results presented at the 67th Annual Meeting of the American Academy of Allergy, Asthma and Immunology.
    • 07 Jun 2010 Results have been presented at the XXIV Congress of The European Academy of Allergy and Clinical Immunology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top